| Date | Title | Description |
| 09.09.2026 | Marengo Therapeutics Completes Enrollment in Phase 1/2 STARt-001 Monotherapy Cohorts and Strengthens Leadership to Advance Invikafusp Alfa Toward Late-Stage Development | Enrollment completed in cohorts evaluating invikafusp alfa monotherapy in PD-1–resistant, antigen-rich solid tumors; updated STARt-001 results selected for oral presentation at the ESMO 2026 Congress
Amy Otto appointed Senior Vice President... |
| 20.07.2026 | Marengo Secures ESMO 2026 Oral Presentation for Key Phase 2 Invikafusp Alfa Data in PD-1–Resistant Solid Tumors and Appoints Pembrolizumab Development Leader Eric Rubin, M.D., to Scientific Advisory B... | Updated STARt-001 results will highlight invikafusp alfa's single-agent activity in PD-1–resistant tumors using a biomarker-enrichment strategy
Eric Rubin, former Senior Vice President of Global Clinical Oncology at Merck, who led the initi... |
| 12.12.2025 | Marengo to Present Initial Results from Invikafusp Alfa and TRODELVY® Combination Study, STARt-002, at the 2025 San Antonio Breast Cancer Symposium | Safety profile of Invikafusp alfa + TRODELVY® is consistent with the known profiles of each agent
Invikafusp alfa demonstrates selective expansion of Vβ6/10 T cells when combined with TRODELVY® in previously treated metastatic breast cancer... |
| 07.11.2025 | Marengo Late-Breaking Oral Presentation Highlights Single-Agent, Pan Tumor Activity of Invikafusp Alfa Across PD-1-Resistant Cancers in Phase 2 Clinical Trial at SITC 2025 | 20% ORR and 80% DCR observed as monotherapy in TMB-H tumors across seven major solid tumor types, including colorectal, lung, breast, gastric, gastroesophageal junction (GEJ), head and neck, and bladder cancers
Clinical activity was consist... |
| 17.10.2025 | Marengo Presents Initial Phase 2 Results Demonstrating Broad Single-Agent Activity of Invikafusp Alfa Across Multiple PD-1-Refractory or -Resistant Solid Tumors as a Late-Breaking Oral Presentation at... | 20.5% ORR and 79% DCR observed in heavily pretreated TMB-H or MSI-H/dMMR tumors across six major solid tumor types, including colorectal, lung, breast, gastric, GEJ, and head and neck cancers
52% of patients experienced target-lesion tumor ... |
| 15.10.2025 | Marengo Therapeutics to Present Key Pipeline Updates at 2025 SITC Annual Meeting and Reveal First Asset from TriSTAR™ Platform Targeting Nectin-4 | Lead program from TriSTAR T cell engager platform targets Nectin-4, a clinically validated tumor antigen overexpressed across multiple solid tumors, including urothelial cancer, NSCLC, TNBC, and esophageal cancer
Collaboration with the Nati... |
| 24.09.2025 | Marengo to Present Late-breaking Clinical Oral Abstract at ESMO 2025 on Initial Phase 2 Data of Invikafusp Monotherapy Activity in Patients with Antigen-Rich Solid Tumors Resistant to Immune Checkpoin... | Data to be presented from the STARt-001 trial demonstrating invikafusp’s single-agent anti-tumor activity in diverse, large cancer indications
CAMBRIDGE, Mass., Sept. 24, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage bio... |
| 18.09.2025 | Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-Directed ADC TRODELVY® in Metastatic Breast Cancer | Completion of Phase 1b safety run-in and determination of recommended Phase 2 dose (RP2D) enables advancement into expansion cohorts for both hormone receptor-positive, HER2-negative (HR+/HER2−) and triple-negative (mTNBC) and metastatic br... |
| 31.07.2025 | Marengo Therapeutics Bolsters Advisory Strength with Appointment of Dr. Mikael Dolsten to its Board of Directors and Dr. Josep Tabernero to its Scientific Advisory Board | Former Chief Scientific Officer & President of R&D at Pfizer, Dr. Mikael Dolsten brings decades of R&D and strategic leadership experience in pharmaceutical medicine to guide Marengo's next phase of growth and value creation
Wor... |
| 02.07.2025 | Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as Late-Breaking Oral Presentation at ESMO Gastrointestinal Cancer... | Promising monotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H) supported by recent FDA fast track designationNew clini... |
| 02.07.2025 | Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as Late-Breaking Oral Presentation at ESMO Gastrointestinal Cancer... | Promising monotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H) supported by recent FDA fast track designationNew clini... |
| 21.05.2025 | Marengo Appoints Dr. Everett Vokes to the Scientific Advisory Board While Advancing Invikafusp alfa Clinical Program in PD-1 Resistant Solid Tumors | Appointment supports continued momentum of the company's rapidly accelerating precision oncology development strategy
CAMBRIDGE, Mass., May 21, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneeri... |
| 21.05.2025 | Marengo Appoints Dr. Everett Vokes to the Scientific Advisory Board While Advancing Invikafusp alfa Clinical Program in PD-1 Resistant Solid Tumors | Appointment supports continued momentum of the company's rapidly accelerating precision oncology development strategy
CAMBRIDGE, Mass., May 21, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneeri... |
| 08.05.2025 | Marengo Doses First Patient in STARt-002 Clinical Trial Evaluating First-in-Class Dual T Cell Agonist, Invikafusp Alfa in Combination with TROP2-directed ADC Trodelvy® in Metastatic Breast Cancer | STARt-002 is a Phase 1b/2 clinical study assessing invikafusp alfa in combination with Gilead's Trodelvy® for HR+/HER2- and TNBC breast cancer patients across leading U.S. and Canadian breast cancer centers
CAMBRIDGE, Mass., May 8, 2025 /PR... |
| 08.05.2025 | Marengo Doses First Patient in STARt-002 Clinical Trial Evaluating First-in-Class Dual T Cell Agonist, Invikafusp Alfa in Combination with TROP2-directed ADC Trodelvy® in Metastatic Breast Cancer | STARt-002 is a Phase 1b/2 clinical study assessing invikafusp alfa in combination with Gilead's Trodelvy® for HR+/HER2- and TNBC breast cancer patients across leading U.S. and Canadian breast cancer centers
CAMBRIDGE, Mass., May 8, 2025 /PR... |
| 25.04.2025 | Marengo to Share Updated Clinical Results from STARt-001 Phase 1/2 Clinical Trial Featuring Invikafusp Alfa Monotherapy Activity in PD1 Resistant Tumors at Upcoming AACR 2025 Clinical Plenary Oral Pre... | Initial disease control rate of 67%, tumor regression rate of 44% and preliminary objective response rate of 22% were observed in TMB-H patients at the optimal biological dose range
Invikafusp alfa (STAR0602) demonstrates pan-tumor selectiv... |
| 25.04.2025 | Marengo to Share Updated Clinical Results from STARt-001 Phase 1/2 Clinical Trial Featuring Invikafusp Alfa Monotherapy Activity in PD1 Resistant Tumors at Upcoming AACR 2025 Clinical Plenary Oral Pre... | Initial disease control rate of 67%, tumor regression rate of 44% and preliminary objective response rate of 22% were observed in TMB-H patients at the optimal biological dose range
Invikafusp alfa (STAR0602) demonstrates pan-tumor selectiv... |
| 25.03.2025 | Marengo to Share Updated Clinical Data of Invikafusp Monotherapy Activity in PD1 resistant tumors in a Clinical Plenary Oral Presentation at AACR 2025 | Data to be presented from the STARt-001 trial demonstrating single agent anti-tumor activity
CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for... |
| 25.03.2025 | Marengo to Share Updated Clinical Data of Invikafusp Monotherapy Activity in PD1 resistant tumors in a Clinical Plenary Oral Presentation at AACR 2025 | Data to be presented from the STARt-001 trial demonstrating single agent anti-tumor activity
CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for... |
| 20.03.2025 | Marengo Enters Multi-Year Collaboration With University of Pennsylvania Institute for Immunology and Immune Health to Advance Next Wave Precision T Cell Immunology Research in Oncology and Autoimmune ... | Collaboration focuses on deeper exploration of Marengo's selective dual T cell agonists in oncology, and expansion of precision T cell depleting platform across a range of autoimmune diseases
Partnership with world-renowned T cell expert E.... |
| 20.03.2025 | Marengo Enters Multi-Year Collaboration With University of Pennsylvania Institute for Immunology and Immune Health to Advance Next Wave Precision T Cell Immunology Research in Oncology and Autoimmune ... | Collaboration focuses on deeper exploration of Marengo's selective dual T cell agonists in oncology, and expansion of precision T cell depleting platform across a range of autoimmune diseases
Partnership with world-renowned T cell expert E.... |
| 03.03.2025 | Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen | Second licensed program created with Marengo's proprietary STAR precision T cell activation platform advances to IND-enabling phase
CAMBRIDGE, Mass., March 3, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology c... |
| 03.03.2025 | Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen | Second licensed program created with Marengo's proprietary STAR precision T cell activation platform advances to IND-enabling phase
CAMBRIDGE, Mass., March 3, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology c... |
| 05.02.2025 | Marengo Therapeutics Announces the Appointment of Elena Garralda, MD, PhD, to its Scientific Advisory Board | Barcelona-based scientific leader brings insights and experience in translational oncology research and clinical development
CAMBRIDGE, Mass., Feb. 5, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company p... |
| 05.02.2025 | Marengo Therapeutics Announces the Appointment of Elena Garralda, MD, PhD, to its Scientific Advisory Board | Barcelona-based scientific leader brings insights and experience in translational oncology research and clinical development
CAMBRIDGE, Mass., Feb. 5, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company p... |
| 10.01.2025 | Marengo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Company presentation scheduled for Thursday, January 16, 2025 at 10AM PT follows recent clinical progress
CAMBRIDGE, Mass., Jan. 10, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel ap... |
| 10.01.2025 | Marengo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Company presentation scheduled for Thursday, January 16, 2025 at 10AM PT follows recent clinical progress
CAMBRIDGE, Mass., Jan. 10, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel ap... |
| 08.01.2025 | Marengo's First-in-Class Invikafusp Alfa (STAR0602) Receives U.S. FDA Fast Track Designation for Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancers with High Tumor Mutationa... | Initial safety and efficacy data from Phase 1 STARt-001 trial showed promising single agent clinical activity in patients with different types of PD-1 resistant tumors including TMB-H colorectal cancer
Global Phase 2 clinical study for invi... |
| 08.01.2025 | Marengo's First-in-Class Invikafusp Alfa (STAR0602) Receives U.S. FDA Fast Track Designation for Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancers with High Tumor Mutationa... | Initial safety and efficacy data from Phase 1 STARt-001 trial showed promising single agent clinical activity in patients with different types of PD-1 resistant tumors including TMB-H colorectal cancer
Global Phase 2 clinical study for invi... |
| 20.12.2024 | Marengo Announces First Patient Dosed in Phase 2 Clinical Study for its Lead Program, Invikafusp Alfa (STAR0602) in PD-1 Resistant Tumors, Expands Study to Europe | Phase 1 STARt-001 data demonstrated a 25% Overall Response Rate and 50% Disease Control Rate observed at the targeted dose range during the Phase 1 investigation in patients harboring PD-1 resistant tumors with high tumor mutation burden, i... |
| 20.12.2024 | Marengo Announces First Patient Dosed in Phase 2 Clinical Study for its Lead Program, Invikafusp Alfa (STAR0602) in PD-1 Resistant Tumors, Expands Study to Europe | Phase 1 STARt-001 data demonstrated a 25% Overall Response Rate and 50% Disease Control Rate observed at the targeted dose range during the Phase 1 investigation in patients harboring PD-1 resistant tumors with high tumor mutation burden, i... |
| 13.12.2024 | Marengo to Present Clinical Data Highlighting Invikafusp Alfa (STAR0602), a First-in-Class Selective, Dual T Cell Agonist at ESMO Immuno-Oncology Congress 2024 | Results further validate company's novel and proprietary STAR bi-specific antibody platform for selective T cell activation in vivo
CAMBRIDGE, Mass., Dec. 13, 2024 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology c... |
| 13.12.2024 | Marengo to Present Clinical Data Highlighting Invikafusp Alfa (STAR0602), a First-in-Class Selective, Dual T Cell Agonist at ESMO Immuno-Oncology Congress 2024 | Results further validate company's novel and proprietary STAR bi-specific antibody platform for selective T cell activation in vivo
CAMBRIDGE, Mass., Dec. 13, 2024 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology c... |
| 09.11.2024 | Marengo Presents Promising First-in-Human Safety, Tolerability and Clinical Activity Data for its Lead Program, Invikafusp Alfa (STAR0602), at the 2024 SITC Annual Meeting | STARt-001 is the first clinical study to evaluate Marengo’s novel, selective Vβ TCR agonist technology to promote in vivo expansion and reprogramming of tumor-infiltrating lymphocytes (TILs) in patients with advanced cancers
Invikafusp alfa... |
| 09.11.2024 | Marengo Presents Promising First-in-Human Safety, Tolerability and Clinical Activity Data for its Lead Program, Invikafusp Alfa (STAR0602), at the 2024 SITC Annual Meeting | STARt-001 is the first clinical study to evaluate Marengo’s novel, selective Vβ TCR agonist technology to promote in vivo expansion and reprogramming of tumor-infiltrating lymphocytes (TILs) in patients with advanced cancers
Invikafusp alfa... |
| 30.10.2024 | Marengo to Unveil First-in-Human Data for its Novel, Selective Dual T Cell Agonist, Invikafusp Alfa (STAR0602) in a Late Breaking Oral Presentation at SITC 2024 Annual Meeting | Marengo's precision Vβ chain targeted T cell activator technology reinvigorates anti-tumor immune responses in refractory tumor models
Invikafusp alfa is being evaluated as a single-agent in an ongoing Phase 1/2 clinical trial (STARt-001) t... |
| 30.10.2024 | Marengo to Unveil First-in-Human Data for its Novel, Selective Dual T Cell Agonist, Invikafusp Alfa (STAR0602) in a Late Breaking Oral Presentation at SITC 2024 Annual Meeting | Marengo's precision Vβ chain targeted T cell activator technology reinvigorates anti-tumor immune responses in refractory tumor models
Invikafusp alfa is being evaluated as a single-agent in an ongoing Phase 1/2 clinical trial (STARt-001) t... |
| 13.09.2024 | Marengo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Invikafusp alfa (STAR0602) and Trodelvy® in both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers | Invikafusp alfa has recently demonstrated single agent clinical activity across different PD-1 resistant cancers in the ongoing START-001 Phase1/2 clinical study
The collaboration plans to evaluate the combination of Marengo's first-in-clas... |
| 13.09.2024 | Marengo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Invikafusp alfa (STAR0602) and Trodelvy® in both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers | Invikafusp alfa has recently demonstrated single agent clinical activity across different PD-1 resistant cancers in the ongoing START-001 Phase1/2 clinical study
The collaboration plans to evaluate the combination of Marengo's first-in-clas... |
| 07.06.2024 | Ipsen and Marengo Therapeutics Announce Second Strategic Partnership to Advance Precision T Cell Engagers from Marengo’s Tri-STAR Platform | Using Marengo’s TriSTAR platform, Ipsen and Marengo teams expand their ongoing oncology research to include up to two additional assets in new early development collaboration
Research will focus on using Marengo’s TriSTAR platform to reinvi... |
| 07.06.2024 | Ipsen and Marengo Therapeutics Announce Second Strategic Partnership to Advance Precision T Cell Engagers from Marengo’s Tri-STAR Platform | Using Marengo’s TriSTAR platform, Ipsen and Marengo teams expand their ongoing oncology research to include up to two additional assets in new early development collaboration
Research will focus on using Marengo’s TriSTAR platform to reinvi... |
| 02.04.2024 | Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen | A novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment
Marengo to receive an associated milestone payment and eligible for additional future milestone payments, and tiered royalties
CAMBRIDGE, Mass., April... |
| 02.04.2024 | Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen | A novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment
Marengo to receive an associated milestone payment and eligible for additional future milestone payments, and tiered royalties
CAMBRIDGE, Mass., April... |
| 07.12.2023 | Marengo Therapeutics and Kings College London Announce Publication in Science Advances Highlighting the Discovery of a New Approach to T Cell Activation | Antibodies to germline-encoded TCR β-chain alleles drive T cells to distinct memory-like effector states and reveal the potential to modulate the germline T cell repertoire.
Innate engagement of the TCR β-chain promotes clinically beneficia... |
| 06.12.2023 | Marengo Therapeutics Announces Publication Describing STAR0602, a Novel, TCR-Targeting Cancer Immunotherapy, in Science Translational Medicine | Marengo's first pan-tumor Vβ T cell activator, STAR0602, expands Vβ6 T cells that drive potent, single agent anti-tumor activity via a distinct mechanism to anti-PD1 therapies
A phase 1/2 clinical study investigation of STAR0602 as a single... |
| 22.03.2023 | Marengo Therapeutics to Present a Late-Breaking Abstract at AACR Annual Meeting 2023 Highlighting Broad Application of its Novel TCR Vβ Targeting Platform | CAMBRIDGE, Mass., March 22, 2023 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel immuno-therapeutics targeting the T cell receptor (TCR) Vβ repertoire to fight cancer and other diseases, today announced that the compa... |
| 01.03.2023 | Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Medical Officer | CAMBRIDGE, Mass., March 1, 2023 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel immuno-therapeutics targeting the T cell receptor (TCR) Vβ to selectively activate the right T cell subsets to fight cancer, today announ... |
| 27.01.2023 | Marengo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of its Novel TCR Vβ Directed Antibody-Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy | START-001 study leverages a biomarker-enriched tissue-agnostic approach to evaluate the activity of STAR0602 monotherapy in checkpoint inhibitor refractory advanced solid tumors
CAMBRIDGE, Mass., Jan. 27, 2023 /PRNewswire/ -- Marengo Thera... |
| 10.11.2022 | Marengo Therapeutics Presents Preclinical Data Supporting Clinical Investigation of its Lead Asset, STAR0602, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting | STAR0602 expands both pre-existing and neoantigen-specific tumor infiltrating Vβ T cell subsets to induce potent anti-tumor activity as monotherapy in PD-1 refractory human and murine tumor models
Comprehensive pharmacology in non-human pr... |
| 28.10.2022 | Marengo Therapeutics Presents Preclinical Proof-of Concept Data for STAR0602, a First-in-class Selective T cell Activator, at the 34th EORTC-NCI-AACR Symposium 2022 | Compelling data with STAR0602 demonstrates potent, single agent anti-tumor activity in PD-1 refractory solid tumor models
Distinct mechanism of action through expansion of a subset of Vβ T cells with a novel memory phenotype that promotes ... |
| 12.10.2022 | Marengo Therapeutics to Give Plenary Oral Presentation at 34th EORTC-NCI-AACR (ENA) Symposium on Lead Program, STAR0602 and Present Additional Data at the SITC Conference Featuring its Vβ-Targeted Sel... | STAR0602 demonstrates potent, single agent anti-tumor activity in refractory solid tumor models, including PD1-refractory setting
Cambridge, Mass. October 11, 2022 – Marengo Therapeutics, Inc., a company pioneering novel therapeutics targe... |
| 16.09.2022 | Marengo Therapeutics Advances First-In-Class Selective T cell Activator, STAR0602, into Human Trials in Solid Tumors and Enters Cooperative Research and Development Agreement with the National Cancer ... | CAMBRIDGE, Mass., Sept. 16, 2022 /PRNewswire/ -- Marengo Therapeutics, a company pioneering novel therapeutics targeting the T cell receptor Vβ chain (TCR Vβ) to selectively activate the right T cell subsets to fight cancer, today announced... |
| 01.08.2022 | Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates from Marengo’s STAR Platform into the Clinic | Multi-year collaboration will sustain Ipsen’s presence in oncology by leveraging Marengo’s novel discovery of TCR Vβ-targeted precision T cell activation approach |
| 01.08.2022 | Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates from Marengo’s STAR Platform into the Clinic | Multi-year collaboration will sustain Ipsen’s presence in oncology by leveraging Marengo’s novel discovery of TCR Vβ-targeted precision T cell activation approach
Ipsen to pay Marengo $45 million upfront with potential for additional miles... |
| 12.07.2022 | Marengo Therapeutics Announces Formation of Scientific Advisory Board to Advance the Company's Development of Novel Therapeutics for Precision Immuno-Oncology | E. John Wherry, Ph.D., and James L. Gulley, M.D., Ph.D., F.A.C.P, named as Co-Chairs
Joined by Lillian L. Siu, M.D., Howard Kaufman, M.D., and Aurélien Marabelle, M.D., Ph.D.
CAMBRIDGE, Mass., July 12, 2022 /PRNewswire/ -- Marengo Therape... |
| 15.06.2022 | Marengo Therapeutics Expands Executive Leadership Team with Svetlana Makhni Joining as Chief Financial Officer | CAMBRIDGE, Mass., June 15, 2022 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel therapeutics that directly target the Vβ chain of the T cell receptor (TCR) to activate the right T cell subsets to fight cancer, today a... |
| 09.05.2022 | Marengo Therapeutics Appoints Ke Liu, MD, PhD, and Bruce Chabner, MD, to Key Leadership Roles, Strengthening Marengo's Development Team and Supporting Translation to the Clinic | Further demonstrates confidence in Marengo's novel T cell biology-focused approach to target TCR Vβ for the activation of anti-tumor immune response with its bi-specific STAR platform
CAMBRIDGE, Mass., May 9, 2022 /PRNewswire/ -- Marengo T... |
| 09.03.2022 | Marengo Therapeutics to Participate in Investor, Scientific, Industry Conferences | CAMBRIDGE, Mass., March 9, 2022 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel therapeutics that selectively activate T cells via the T cell receptor Vβ chain to combat cancer, today announced that it will participat... |
| 06.01.2022 | Marengo Therapeutics to Present at Annual J.P. Morgan Health Care Conference | CAMBRIDGE, Mass., Jan. 6, 2022 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel therapeutics that directly target the Vβ chain of the T cell receptor (TCR) to activate the right T cell subsets to fight cancer, today an... |
| 08.11.2021 | Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform | Differentiated platform built on its groundbreaking discovery of T cell activation via direct antibody targeting of Vβ TCR variants |
| 08.11.2021 | Marengo Therapeutics Raises $80M in Funding | Marengo Therapeutics, a Cambridge MA-based company pioneering first-in-class therapeutics that activate the right immune response to promote lifelong protection against cancer, raised $80M in funding.
ATP made the launch investment.
The com... |
| 08.11.2021 | Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform | Differentiated platform built on its groundbreaking discovery of T cell activation via direct antibody targeting of Vβ TCR variants
First-in-class lead molecule slated to enter clinic in 2022
Cambridge, Mass. November 8, 2021 – ATP, a lea... |
| 08.11.2021 | Marengo Therapeutics Launches with $80M |
CAMBRIDGE, MA, Marengo Therapeutics launches with $80 million financing.
>> Click here for more funding data on Marengo Therapeutics
>> To export Marengo Therapeutics funding data to PDF and Excel, click here
ATP announce... |
